Journal of Peking University(Health Sciences) ›› 2018, Vol. 50 ›› Issue (6): 1004-1008. doi: 10.19723/j.issn.1671-167X.2018.06.011

• Article • Previous Articles     Next Articles

Clinical and immunological characteristics of patients with systemic lupus erythematosus in Tibet plateau, China

Jiao YANG1,Hai-hong YAO2,Xiao-dong MO3,Zeng LUO1,yang-jin Bai-ma1,()   

  1. 1. Department of Rheumatology and Immunology, Tibet Autonomous Region People’s Hospital, Lhasa 850000, China
    2. Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing 100044, China
    3. Department of Hemotology, Peking University People’s Hospital, Beijing 100044, China
  • Received:2018-03-29 Online:2018-12-18 Published:2018-12-18
  • Contact: yang-jin Bai-ma E-mail:19960004@tarph.com

Abstract:

Objective: To describe the clinical, immunological characteristics and organ involvement of patients with systemic lupus erythematosus (SLE) in Tibet plateau, China.Methods:We retrospectively investigated 70 patients admitted in the Tibet Autonomous Region People’s Hospital between May 2014 and April 2016. In the study, 120 hospitalized patients with SLE from the Department of Rheumatology and Immunology of the Peking University People’s Hospital were randomly selected as the control (plain) group. The major organ involvement, clinical and immunological characteristics were compared between the two groups.Results:The female to male ratio of Tibet plateau group was 10.7, while the correspon-ding ratio of plain group was 11.0. The mean age at disease diagnosis was (32.21±11.40) and (35.38±13.25) years, respectively. the most common initial manifestations of SLE were arthritis (78.6%), alopecia (55.7%) and malar rash (48.6%) in Tibet plateau group, the prevalence of arthritis and alopecia was significantly higher than in plain group (P<0.05). The incidence of neuropsychiatric and kidney involvement was significantly lower in Tibet plateau group compared with plain group (P<0.05). As for the serological manifestations, the positivity of anti-double-stranded DNA (dsDNA) (57.1%), anti-Smith (Sm) antibody (55.7%), anti-Sj?gren syndrome A (SSA) antibody (72.3%), anti-Sj?gren syndrome B (SSB) antibody (41.4%) and anti-u1-ribosenuclear protein (u1RNP) antibody (45.7%) was significantly higher in Tibet plateau group (P<0.05). While the incidence of low serum complement C3 (61.4%), C4 (38.6%) less frequent in Tibet plateau group. Mean SLE disease activity index (SLEDAI) score was similar in the Tibet plateau group (12.18±5.58) and plain group (12.69±7.28). Moreover, there were 13 (18.6%) SLE patients suffering from tuberculosis and 7 (10%) SLE patients infected with hepatitis B virus in Tibet plateau group. The number of recent-onset SLE patients with lower 25-dihydroxy-vitamin D3 (25-OH-VD3) in Tibet plateau group was fewer than that in the plain group (76.7% vs. 90.0%, P=0.046). Serum 25-OH-VD3 levels in Tibet plateau plateau group were (31.14±18.74) nmol/L, those in plain group were (26.91±14.27) nmol/L, and the difference was not significant.Conclusion:The age, gender and SLEDAI scores in Tibet plateau group was similar to those in plain group. But there are significant differences in clinical manifestations, distributions of antibodies and immunological changes between Tibet plateau group and plain group. The patients with lower serum 25-OH-VD3 levels were more in plain group than in Tibet plateau group, while there was no signi-ficant difference in the 25-OH-VD3 level between the two groups.

Key words: Lupus erythematosus, systemic, Tibet, Biological markers, Symptoms and signs

CLC Number: 

  • R593.241

Table 1

Comparison of general situation in SLE patients between the Tibet plateau group and the plain group"

General situation Tibet plateau
group (n=70)
Plain group
(n=120)
P
Female, n(%) 64 (91.4) 110 (91.7) 0.955
Onset age/years, x-±s 33.21±11.40 35.38±13.25 0.213
SLEDAI score, x-±s 12.19±5.58 12.69±7.28 0.596

Table 2

Comparison of common clinical features in SLE patients between Tibet plateau group and plain group n(%)"

Clinical features Tibet plateau
group (n=70)
Plain group
(n=120)
P
Malar rash 34 (48.6) 65 (54.2) 0.456
Arthritis 55 (78.6) 45 (37.5) <0.001
Hair loss 39 (55.7) 38 (31.7) 0.001
Fever 17 (27.3) 36 (30.0) 0.397
Oral ulcers 17 (27.3) 19 (15.8) 0.152
Raynaud phenomenon 4 (5.7) 15 (12.5) 0.133

Table 3

Comparison of involved organs in SLE patients between the Tibet plateau group and the plain group"

Items Tibet plateau
group (n=70)
Plain group
(n=120)
P
Blood system 49 (70.0) 76 (63.3) 0.350
Urinary system
Lupus nephritis 27 (38.6) 68 (56.7) 0.016
Cystitis 0 1 (0.8) >0.990
Retinal vasculitis 2 (4.3) 4 (3.3) >0.990
Neuropsychiatric lupus 2 (2.9) 21 (17.5) 0.003
Respiratory system
Interstitial lung disease/
Pulmonary fibrosis
6 (8.6) 16 (13.3) 0.322
Valvular hemorrhage 3 (4.3) 4 (3.3) 0.709
Cardiovascular system
Valvular heart disease 0 2 (1.7) >0.992
Pulmonary hypertension 6 (8.6) 15 (12.5) 0.405
Digestive system
Autoimmune pancreatitis 2 (2.9) 2 (1.7) 0.623
Mesenteric vasculitis 2 (2.9) 4 (3.3) >0.989
Liver injury 3 (4.3) 12 (10.0) 0.163
Myositis 2 (2.9) 10 (8.3) 0.131

Table 4

Serological comparison of SLE patients in the Tibet plateau group and the plain groupn(%)"

Items Tibet plateau
group (n=70)
Plain group
(n=120)
P
ANA+ 66(94.3) 112(93.3) 0.795
Anti-dsDNA+ 40(57.1) 48(40.0) 0.022
Anti-Sm+ 39(55.7) 10(8.3) <0.001
Anti-SSA+ 52(74.3) 40(33.3) <0.001
Anti-SSB+ 29(41.4) 7(5.8) <0.001
Anti-u1RNP+ 32(45.7) 24(20.0) <0.001
ACL+ 16(22.9) 33(27.5) 0.480
C3↓ 43(61.4) 105(87.5) <0.001
C4↓ 27(38.6) 92(76.7) <0.001

Figure 1

SLE patients with 25-OH-VD3 reducedA, comparison of systemic lupus erythematosus (SLE) patients 25-dihydroxy-vitamin D3 (25-OH-VD3) reduced between the Tibet plateau group and plain group; B, comparison of the SLE disease activity index (SLEDAI) scores between 25-OH-VD3 reduced group and normal group in SLE patients of Tibet plateau group; C, analysis of 25-OH-VD3 level and anti-double-stranded DNA (dsDNA) in Tibet plateau group (P=0.57); D, analysis of 25-OH-VD3 level and lupus nephritis (LN) in Tibet plateau group (P=0.84)."

[1] 中华医学会风湿病学分会. 系统性红斑狼疮诊断及治疗指南[J]. 中华风湿病学杂志, 2010,14(5):342-346.
[2] Hochberg MC . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus[J]. Arthritis Rheum, 1997,40(9):1725.
[3] Bombardier C, Gladman DD, Urowitz MB , et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE[J]. Arthritis Rheum, 1992,35(6):630-640.
doi: 10.1002/(ISSN)1529-0131
[4] WS288—2008, 中华人民共和国卫生行业标准:肺结核诊断[S].
[5] WS299—2008, 中华人民共和国卫生行业标准:乙型病毒性肝炎诊断标准[S].
[6] Li M, Zhang W, Leng X , et al. Chinese SLE Treatment and Research group (CSTAR) registry: Ⅰ. Major clinical characteristics of Chinese patients with systemic lupus erythematosus[J]. Lupus, 2013,22(11):1192-1199.
doi: 10.1177/0961203313499086 pmid: 23963101
[7] Zhang S, Su J, Li X , et al. Chinese SLE Treatment and Research group (CSTAR) registry: Ⅴ. gender impact on Chinese patients with systemic lupus erythematosus[J]. Lupus, 2015,24(12):1267-1275.
doi: 10.1177/0961203315585813 pmid: 25972364
[8] 胡莉娜, 吴丽娟, 古宇 , 等. 地震伤员藏族人群在急进平原治疗前后红细胞及相关参数的分析[J]. 国际检验医学杂志, 2012,33(2):174-175.
doi: 10.3969/j.issn.1673-4130.2012.02.019
[9] 胡海燕, 王亚魁, 张志刚 . 中医治疗高原脱发120例疗效观察[J]. 西藏科技, 2002(10):52.
[10] 罗洋, 杜华, 杨桂兰 , 等. 红景天治疗高原性脱发的临床研究[J]. 西北国防医学杂志, 2015,36(12):808-810.
[11] Kuhn A, Beissert S . Photosensitivity in lupus erythematosus[J]. Autoimmunity, 2005,38(7):519-529.
doi: 10.1080/08916930500285626
[12] Foltyn VN, Golan TD . In vitro ultraviolet irradiation induces pro-inflammatory responses in cells from premorbid SLE mice[J]. Lupus, 2001,10(4):272-283.
doi: 10.1191/096120301680416968 pmid: 11341104
[13] Ni JD, Yao X, Pan HF , et al. Clinical and serological correlates of anti-Sm autoantibodies in Chinese patients with systemic lupus erythematosus: 1 584 cases[J]. Rheumatol Int, 2009,29(11):1323-1326.
doi: 10.1007/s00296-009-0855-1 pmid: 19194707
[14] 黄菁梅, 李小冬, 谭焕源 , 等. 系统性红斑狼疮患者抗u1RNP抗体检测的临床意义[J]. 临床肺科杂志, 2010,15(5):734-735.
doi: 10.3969/j.issn.1009-6663.2010.05.078
[15] 罗靓, 何英 . 狼疮脑病的临床治疗概述[J]. 中国中医急症, 2017,26(1):91-94.
doi: 10.3969/j.issn.1004-745X.2017.01.028
[16] 平措卓玛. 2010 年西藏自治区结核病监测资料分析[J]. 疾病监测, 2013 ( 4):269-271.
[17] 陈红梅, 国杰, 胡凤梅 . 2011—2013年西藏自治区结核病流行特征分析[J]. 现代预防医学, 2015,42(16):2887-2889.
[1] XU Ying, Ci-ren-yang-jin. Analysis of the relationship between high altitude polycythemia and peptic ulcer bleeding [J]. Journal of Peking University (Health Sciences), 2022, 54(1): 161-165.
[2] Jia-yi TIAN,Xia ZHANG,Gong CHENG,Qing-hong LIU,Shi-yang WANG,Jing HE. Serum interleukin-2 receptor α as a clinical biomarker in patients with systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1083-1087.
[3] Jian-mei ZOU,Li-jun WU,Cai-nan LUO,Ya-mei SHI,Xue WU. Relationship of serum 25- hydroxy vitamin D and systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 938-941.
[4] Zheng-fang LI,Xue WU,Li-jun WU,Cai-nan LUO,Ya-mei SHI,Yan ZHONG,Xiao-mei CHEN,Xin-yan MENG. Clinical features of patients with Rhupus syndrome [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 933-937.
[5] MA Xiang-bo,ZHANG Xue-wu,JIA Ru-lin,GAO Ying,LIU Hong-jiang,LIU Yu-fang,LI Ying-ni. Application of lymphocytes test in peripheral blood of patients with systemic sclerosis during the treatment [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 721-727.
[6] ZHANG Lei,LI Guo-liang,DANG Zong-hui, ,A yong,WU Ling-jie,LIU Li-jun. Analysis of bleeding risk in percutaneous renal biopsy in Tibet [J]. Journal of Peking University (Health Sciences), 2021, 53(2): 298-301.
[7] XIA Fang-fang,LU Fu-ai,LV Hui-min,YANG Guo-an,LIU Yuan. Clinical characteristics and related factors of systemic lupus erythematosus with interstitial pneumonia [J]. Journal of Peking University (Health Sciences), 2021, 53(2): 266-272.
[8] Jing ZHAO,Feng SUN,Yun LI,Xiao-zhen ZHAO,Dan XU,Ying-ni LI,Yu-hui LI,Xiao-lin SUN. Significance of anti-tubulin-α-1C autoantibody in systemic sclerosis [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1009-1013.
[9] Qian GUO, Xiao-xu MA, Hui GAO, Lian-jie SHI, Yu-chao ZHONG, Lin-feng XIE, Miao SHAO, Xue-wu ZHANG. Association of Semaphorin 3A with thrombocytopenia in systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2020, 52(5): 892-896.
[10] Yan GENG,Bo-rui LI,Zhuo-li ZHANG. Musculoskeletal ultrasound findings of symptomatic joints in patients with systemic lupus erythematosus [J]. Journal of Peking University(Health Sciences), 2020, 52(1): 163-168.
[11] Ying-ni LI,Xiao-hong XIANG,Jing ZHAO,Yun LI,Feng SUN,Hong-yan WANG,Ru-lin JIA,Fan-lei HU. Significance of anti-carbamylated fibrinogen antibodies in systemic lupus erythematosus [J]. Journal of Peking University(Health Sciences), 2019, 51(6): 1019-1024.
[12] Yu-hua WANG,Guo-hua ZHANG,Ling-ling ZHANG,Jun-li LUO,Lan GAO. Adrenal hemorrhage in a patient with systemic lupus erythematosus [J]. Journal of Peking University(Health Sciences), 2019, 51(6): 1178-1181.
[13] Hong-lin ZHU,Qian DU,Wei-lin CHEN,Xiao-xia ZUO,Quan-zhen LI,Si-jia LIU. Altered serum cytokine expression profile in systemic sclerosis and its regulatory mechanisms [J]. Journal of Peking University(Health Sciences), 2019, 51(4): 716-722.
[14] Yi-ying YANG,Xiao-xia ZUO,Hong-lin ZHU,Si-jia LIU. Advances in epigenetic markers of dermatomyositis/polymyositis [J]. Journal of Peking University(Health Sciences), 2019, 51(2): 374-377.
[15] Xiao-hui ZHANG,Xue-rong DENG,Fan Li,Ying ZHU,Zhuo-li ZHANG. Posterior reversible encephalopathy syndrome in systemic lupus erythematosus: a case report [J]. Journal of Peking University(Health Sciences), 2018, 50(6): 1102-1107.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] . [J]. Journal of Peking University(Health Sciences), 2009, 41(4): 456 -458 .
[2] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 125 -128 .
[3] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 135 -140 .
[4] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 158 -161 .
[5] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 217 -220 .
[6] . [J]. Journal of Peking University(Health Sciences), 2009, 41(1): 52 -55 .
[7] . [J]. Journal of Peking University(Health Sciences), 2009, 41(1): 109 -111 .
[8] . [J]. Journal of Peking University(Health Sciences), 2009, 41(3): 297 -301 .
[9] . [J]. Journal of Peking University(Health Sciences), 2009, 41(5): 599 -601 .
[10] . [J]. Journal of Peking University(Health Sciences), 2009, 41(5): 516 -520 .